Review| Volume 13, ISSUE 5, P315-324, October 2013

Download started.


Pertuzumab in Breast Cancer: A Systematic Review


      Pertuzumab is a monoclonal antibody that represents the first among a new class of agents known as human epidermal growth factor receptor (HER) dimerization inhibitors. This is the first systematic review according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines to synthesize all available data of pertuzumab in breast cancer. The search strategy retrieved 11 studies that evaluated pertuzumab. One study was conducted in the neoadjuvant setting (417 patients), whereas all the others dealt with patients with recurrent, metastatic, or refractory disease (1023 patients). Six studies were conducted in HER2+ breast cancer population (1354 patients), whereas 5 studies (86 patients) were conducted in HER2 (or unknown HER2 status) disease. Pertuzumab is the most recent agent approved by the US Food and Drug Administration in combination with trastuzumab and docetaxel for the treatment of patients with HER2+ metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease. This approval has been based on data from a phase III Clinical Evaluation of Pertuzumab and Trastuzumab (CLEOPATRA) study. The antitumor activity with the significant reduction in the risk of progression or death, as reflected upon the increase of 6.1 months in median progression-free survival, indicates that pertuzumab may provide an avenue for achieving additional benefit for patients with HER2+. Moreover, pertuzumab seems to have a putative role in the management of patients with HER2 who are resistant to trastuzumab. The promising role of pertuzumab in the neoadjuvant and adjuvant settings remains to be further investigated and established in the future.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Clinical Breast Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • American Cancer Society
        Cancer Facts and Figures 2012.
        American Cancer Society, Atlanta2012 (Available at) (Accessed May 21, 2013)
        • Perez E.A.
        • Romond E.H.
        • Suman V.J.
        • et al.
        Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31.
        J Clin Oncol. 2011; 29: 3366-3373
        • Morris S.R.
        • Carey L.A.
        Trastuzumab and beyond: new possibilities for the treatment of HER2-positive breast cancer.
        Oncology (Williston Park). 2006; 20: 1763-1776
        • Cho H.S.
        • Mason K.
        • Ramyar K.X.
        • et al.
        Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab.
        Nature. 2003; 421: 756-760
        • Yarden Y.
        • Sliwkowski M.X.
        Untangling the ErbB signalling network.
        Nat Rev Mol Cell Biol. 2001; 2: 127-137
        • Harari D.
        • Yarden Y.
        Molecular mechanisms underlying ErbB2/HER2 action in breast cancer.
        Oncogene. 2000; 19: 6102-6114
        • Agus D.B.
        • Akita R.W.
        • Fox W.D.
        • et al.
        Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth.
        Cancer Cell. 2002; 2: 127-137
        • Fendly B.M.
        • Winget M.
        • Hudziak R.M.
        • et al.
        Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product.
        Cancer Res. 1990; 50: 1550-1558
        • Arteaga C.L.
        ErbB-targeted therapeutic approaches in human cancer.
        Exp Cell Res. 2003; 284: 122-130
        • Schaefer G.
        • Fitzpatrick V.D.
        • Sliwkowski M.X.
        Gamma-heregulin: a novel heregulin isoform that is an autocrine growth factor for the human breast cancer cell line, MDA-MB-175.
        Oncogene. 1997; 15: 1385-1394
        • Franklin M.C.
        • Carey K.D.
        • Vajdos F.F.
        • et al.
        Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex.
        Cancer Cell. 2004; 5: 317-328
        • Badache A.
        • Hynes N.E.
        A new therapeutic antibody masks ErbB2 to its partners.
        Cancer Cell. 2004; 5: 299-301
        • Nahta R.
        • Hung M.C.
        • Esteva F.J.
        The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells.
        Cancer Res. 2004; 64: 2343-2346
        • Agus D.B.
        • Akita R.W.
        • Fox W.D.
        • et al.
        A potential role for activated HER-2 in prostate cancer.
        Semin Oncol. 2000; 27 (discussion 92-100): 76-83
        • Malik M.
        • Totpal K.
        • Balter I.
        Dose response studies of recombinant humanized monoclonal antibody 2C4 (pertuzumab) in tumor xenograft models.
        Proc Am Assoc Cancer Res. 2003; 44: 773
        • Lewis G.D.
        • Lofgren J.A.
        • McMurtrey A.E.
        • et al.
        Growth regulation of human breast and ovarian tumor cells by heregulin: evidence for the requirement of ErbB2 as a critical component in mediating heregulin responsiveness.
        Cancer Res. 1996; 56: 1457-1465
        • Friess T.
        • Bauer S.
        • Burger A.M.
        In vivo activity of recombinant humanised monoclonal antibody 2C4 in xenografts is independent of tumour type and degree of HER-2 overexpression.
        EORTC-NCI-AACR Conference, Frankfurt, Germany, 2002 (abstract 953)
        • Mendoza N.
        • Phillips G.L.
        • Silva J.
        • et al.
        Inhibition of ligand-mediated HER2 activation in androgen-independent prostate cancer.
        Cancer Res. 2002; 62: 5485-5488
        • Mann M.
        • Sheng H.
        • Shao J.
        • et al.
        Targeting cyclooxygenase 2 and HER-2/neu pathways inhibits colorectal carcinoma growth.
        Gastroenterology. 2001; 120: 1713-1719
        • Liberati A.
        • Altman D.G.
        • Tetzlaff J.
        • et al.
        The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration.
        J Clin Epidemiol. 2009; 62: e1-34
        • Lu D.
        • Burris 3rd, H.A.
        • Wang B.
        • et al.
        Drug interaction potential of trastuzumab emtansine combined with pertuzumab in patients with HER2-positive metastatic breast cancer.
        Curr Drug Metab. 2012; 13: 911-922
        • Cortés J.
        • Fumoleau P.
        • Bianchi G.V.
        • et al.
        Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer.
        J Clin Oncol. 2012; 30: 1594-1600
        • Gianni L.
        • Pienkowski T.
        • Im Y.H.
        • et al.
        Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.
        Lancet Oncol. 2012; 13: 25-32
        • Baselga J.
        • Cortés J.
        • Kim S.B.
        • et al.
        Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.
        N Engl J Med. 2012; 366: 109-119
        • Gianni L.
        • Lladó A.
        • Bianchi G.
        • et al.
        Open-label, phase II, multicenter, randomized study of the efficacy and safety of two dose levels of pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2-negative metastatic breast cancer.
        J Clin Oncol. 2010; 28: 1131-1137
        • Baselga J.
        • Gelmon K.A.
        • Verma S.
        • et al.
        Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy.
        J Clin Oncol. 2010; 28: 1138-1144
        • Yamamoto N.
        • Yamada Y.
        • Fujiwara Y.
        • et al.
        Phase I and pharmacokinetic study of HER2-targeted rhuMAb 2C4 (pertuzumab, RO4368451) in Japanese patients with solid tumors.
        Jpn J Clin Oncol. 2009; 39: 260-266
        • Portera C.C.
        • Walshe J.M.
        • Rosing D.R.
        • et al.
        Cardiac toxicity and efficacy of trastuzumab combined with pertuzumab in patients with [corrected] human epidermal growth factor receptor 2-positive metastatic breast cancer.
        Clin Cancer Res. 2008; 14: 2710-2716
        • Agus D.B.
        • Gordon M.S.
        • Taylor C.
        • et al.
        Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer.
        J Clin Oncol. 2005; 23: 2534-2543
        • Attard G.
        • Kitzen J.
        • Blagden S.P.
        • et al.
        A phase Ib study of pertuzumab, a recombinant humanised antibody to HER2, and docetaxel in patients with advanced solid tumours.
        Br J Cancer. 2007; 97: 1338-1343
        • Albanell J.
        • Montagut C.
        • Jones E.T.
        • et al.
        A phase I study of the safety and pharmacokinetics of the combination of pertuzumab (rhuMab 2C4) and capecitabine in patients with advanced solid tumors.
        Clin Cancer Res. 2008; 14: 2726-2731
        • Miller K.
        • Gianni L.
        • Andre F.
        • et al.
        A phase Ib/II trial of trastuzumab-DM1 (T-DM1) with pertuzumab (P) for women with HER2-positive, locally advanced or metastatic breast cancer (BC) who were previously treated with trastuzumab (T).
        J Clin Oncol. 2010; 28 (15s):abstract 1012
        • Dawood S.
        • Broglio K.
        • Buzdar A.U.
        • et al.
        Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review.
        J Clin Oncol. 2010; 28: 92-98
        • Slamon D.J.
        • Leyland-Jones B.
        • Shak S.
        • et al.
        Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
        N Engl J Med. 2001; 344: 783-792
        • Marty M.
        • Cognetti F.
        • Maraninchi D.
        • et al.
        Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.
        J Clin Oncol. 2005; 23: 4265-4274
        • Baselga J.
        • Swain S.M.
        CLEOPATRA: a phase III evaluation of pertuzumab and trastuzumab for HER2-positive metastatic breast cancer.
        Clin Breast Cancer. 2010; 10: 489-491
        • Perez E.A.
        • Lopez-Vega J.M.
        • Del Mastro L.
        • et al.
        A combination of pertuzumab, trastuzumab, and vinorelbine for first-line treatment of patients with HER2-positive metastatic breast cancer: an open-label, two-cohort, phase II study (VELVET).
        J Clin Oncol. 2012; (30s:abstract TPS653)
        • Rimawi M.F.
        • Poole C.J.
        • Ferrero J.M.
        • et al.
        Pertuzumab in combination with trastuzumab plus an aromatase inhibitor in patients with hormone receptor-positive, HER2-positive metastatic breast cancer: a randomized phase II study (PERTAIN).
        J Clin Oncol. 2012; (30s:abstract TPS654)
        • Walshe J.M.
        • Denduluri N.
        • Berman A.W.
        • et al.
        A phase II trial with trastuzumab and pertuzumab in patients with HER2-overexpressed locally advanced and metastatic breast cancer.
        Clin Breast Cancer. 2006; 6: 535-539
        • Baselga J.
        • Bradbury I.
        • Eidtmann H.
        • et al.
        Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial.
        Lancet. 2012; 379: 633-640
        • Schneeweiss A.
        • Chia S.
        • Hickish T.
        • et al.
        Neoadjuvant pertuzumab and trastuzumab concurrent or sequential with an anthracycline-containing or concurrent with an anthracycline-free standard regimen: a randomized phase II study (TRYPHAENA).
        Cancer Res. 2011; 71: 112s
        • De Keulenaer G.W.
        • Doggen K.
        • Lemmens K.
        The vulnerability of the heart as a pluricellular paracrine organ: lessons from unexpected triggers of heart failure in targeted ErbB2 anticancer therapy.
        Circ Res. 2010; 106: 35-46
        • Okoshi K.
        • Nakayama M.
        • Yan X.
        • et al.
        Neuregulins regulate cardiac parasympathetic activity: muscarinic modulation of beta-adrenergic activity in myocytes from mice with neuregulin-1 gene deletion.
        Circulation. 2004; 110: 713-717
        • Gassmann M.
        • Casagranda F.
        • Orioli D.
        • et al.
        Aberrant neural and cardiac development in mice lacking the ErbB4 neuregulin receptor.
        Nature. 1995; 378: 390-394
        • Zhao Y.Y.
        • Sawyer D.R.
        • Baliga R.R.
        • et al.
        Neuregulins promote survival and growth of cardiac myocytes. Persistence of ErbB2 and ErbB4 expression in neonatal and adult ventricular myocytes.
        J Biol Chem. 1998; 273: 10261-10269
        • Lenihan D.
        • Suter T.
        • Brammer M.
        • et al.
        Pooled analysis of cardiac safety in patients with cancer treated with pertuzumab.
        Ann Oncol. 2012; 23: 791-800
        • Towndrow K.M.
        • Dybdal N.
        • Nguyen L.T.
        • et al.
        Effects of chronic pertuzumab-mediated HER2 pathway inhibition.
        Society of Toxicology, Baltimore, MD, March 21-25, 2004 (abstract 76)
        • Rich J.N.
        • Rasheed B.K.
        • Yan H.
        EGFR mutations and sensitivity to gefitinib.
        N Engl J Med. 2004; 351: 1260-1261
        • Drucker A.M.
        • Wu S.
        • Dang C.T.
        • et al.
        Risk of rash with the anti-HER2 dimerization antibody pertuzumab: a meta-analysis.
        Breast Cancer Res Treat. 2012; 135: 347-354
        • Edgerly M.
        • Fojo T.
        Is there room for improvement in adverse event reporting in the era of targeted therapies?.
        J Natl Cancer Inst. 2008; 100: 240-242